SCHEMBL6940919

SCHEMBL6940919

O=[N+]([O-])c1ccc(CS(=O)(=O)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.53
FAAH O00519 1/20 0.52
PRSS1 P07477 1/20 0.52
PRSS2 P07478 1/20 0.52
ELANE P08246 1/20 0.52
PRTN3 P24158 1/20 0.52
PRSS3 P35030 1/20 0.52
HTT P42858 1/20 0.51
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
CA1 P00915 5/20 0.49
CA2 P00918 5/20 0.49
CA9 Q16790 4/20 0.49
CA12 O43570 3/20 0.49
CA14 Q9ULX7 2/20 0.49
IDO1 P14902 2/20 0.48
CA7 P43166 2/20 0.48
CA5A P35218 2/20 0.48
CA3 P07451 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28357735 0.83 LOXL2 (0.57) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL294284 0.82 LOXL2 (0.55) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL31540565 0.81 TSHR (0.56) LOXL2TSHRCA1CA2CA9
Lithium Ion SCHEMBL8022514 0.80 LOXL2 (0.53) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL515030 0.80 LOXL2 (0.53) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL1425399 0.80 LOXL2 (0.53) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL515031 0.80 LOXL2 (0.53) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL2999944 0.80 CA2 (0.59) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL1425484 0.80 LOXL2 (0.53) LOXL2HTTTSHRMEN1KMT2A
SCHEMBL294285 0.80 LOXL2 (0.59) LOXL2HTTTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030170811-A1 Process for the production of alpha-human atrial natriuretic polypeptide FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-11 US disclosed
US-6403336-B1 DNA SEGMENT ENCODES PROTECTIVE PEPTIDE-FUSED ATRIOPEPTIN; MICROORGANISMS TRANSFORMED WITH VECTORS; GENETIC ENGINEERING FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
EP-0206769-B2 A process for the production of alpha-human atrial natriuretic polypeptide FUJISAWA PHARMACEUTICAL CO (JP) 1999-11-10 EP disclosed
US-5360935-A From phenylmethanesulfonyl fluorides and phenylacyl bromides, phase transfer agent, base, solvent NIHON BAYER AGROCHEM K.K. (JP) 1994-11-01 US disclosed
EP-0534249-A2 Process for the preparation of 3-phenyl-2-propenones NIHON BAYER AGROCHEM K.K. (JP) 1993-03-31 EP disclosed
EP-0440311-A1 A process for the production of alpha-human atrial natriuretic polypeptide FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-08-07 EP disclosed
EP-0206769-A2 A process for the production of alpha-human atrial natriuretic polypeptide FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170811-A1 Process for the production of alpha-human atrial natriuretic polypeptide NPPA, NPR1, NPR3 LOXL2 4715/4885FAAH 2511/4885PRSS1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.